{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for dimethyl root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT01111955: Phase 2 Interventional Completed Diabetes Mellitus, Type 2
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ACHIRAL)
Clobenzepam (tarpane) is a drug exhibiting antihistaminic properties.
Status:
Class (Stereo):
CHEMICAL (MIXED)
Cethexonium is a cyclohexanols derivative with antimicrobial activities.
Status:
Investigational
Source:
NCT00481520: Phase 2 Interventional Completed Alzheimer Disease
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Cerlapirdine is a selective and potent full antagonist of the serotonin 6 (5-HT6) receptor that has been investigated by Wyeth and Pfizer for the treatment of Alzheimer Disease.
Status:
Investigational
Class (Stereo):
CHEMICAL (MIXED)
Dimefadane is the indanamine derivative. It was developed as analgesic.
Status:
Investigational
Source:
NCT04176848: Phase 2 Interventional Active, not recruiting Breast Cancer
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT02260648: Phase 3 Interventional Terminated Hypercholesterolemia
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Evacetrapib (LY2484595) is a novel benzazepine-based CETP inhibitor that has been developed at Lilly Research Laboratories. Evacetrapib inhibits CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. On 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784).
Class (Stereo):
CHEMICAL (ABSOLUTE)
Metergotamine (MY-25 or 1-methyl-ergotamine-bitartrate) is a derivative of ergotamine and belongs to peptide alkaloids. It exerts a dampening effect on vessels, in that relaxation is brought about in contracted vessels, whereas contraction is brought in dilated vessels. Metergotamine was being studied in migraine prophylaxis.
Status:
Investigational
Source:
NCT01021553: Phase 2 Interventional Completed Premature Ejaculation
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Epelsiban (GSK557296), a pyridyl-2,5-diketopiperazine, is a potent, highly selective, and orally bioavailable non-peptide oxytocin receptor antagonist. GlaxoSmithKline was developing epelsiban for the treatment of women infertility due to adenomyosis and premature ejaculation.
Status:
Investigational
Source:
NCT01390714: Phase 1 Interventional Completed Gastroesophageal Reflux Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
E-3710 (Z-215) is a new proton pump inhibitor (PPI). E-3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment. E-3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease. E-3710 is metabolized through oxidation, reduction and conjugation. Unchanged E-3710 was excreted in urine at trace levels but was not detected in faces. The major isozyme contributing to the oxidation of Z-215, including the formation of Z-215 sulphone, was CYP3A4. It is useful for treating gastroesophageal reflux disease in all CYP2C19 genotypes. E-3710 is in phase II clinical trial for the treatment of erosive esophagitis and gastro-esophageal reflux.
